Atrial Natriuretic Peptide (ANP) ELISA Kit

  • Created on the 16 May, 2017.


Human ANP ELISA kit is a procedure intended for determining in vitro quantitative amounts of atrial natriuretic peptide (ANP, ANF, ANH) in human serum, cell lysates, plasma, other biological fluids and cell culture supernatant. This assay has a minimum sensitivity limit of 2.52 ug/ml.


Atrial natriuretic peptide (ANP) can also be referred to as atrial natriuretic hormone (ANH), atrial natriuretic factor (ANF), atriopeptin, cardionatrine and cardiodilatin. It is a 28 amino acid polypeptide hormone which is secreted by heart muscle cells, a powerful vasodilator. ANP is responsible for reducing the blood pressure by regulating homeostatic control of the body water, fat, sodium and potassium levels. It is often released by muscles cells in the atria of the heart in response to high blood volume. It can be secreted in response to raised sodium concentration, stretching of the atrial wall, endothelin, increased sympathetic stimulation of β-adrenoceptors and exercise. ANP is able to bind to a specific set of receptors which are called ANP receptors, this results in reducing blood volume, systemic blood pressure and a reduction in cardiac output. Generally, the function of ANP is to counter the increase in the volume and pressure of blood that is caused via the renin-angiotensin system. ANP and many of its related peptides are important biomarkers for many cardiovascular diseases such as coronary artery disease, stroke, heart failure and myocardial infarction. Also, recombinant human ANP has been approved in Japan to be used in order to treat patients experiencing heart failure. ANP ELISA kit is ideal for use in many different diagnostic applications.


The minimum detection sensitivity level of atrial natriuretic peptide (ANP, ANH, ANF) using current human ANP ELISA kit was 2.52 ug/ml. The dynamic range for this assay is 5.0 – 1,000.0 ug/ml.


  1. Human atrial natriuretic peptide treatment for acute heart failure: a systematic review of efficacy and mortality. Can J Cardiol. (2012) 28 (1): 102-9. Review. Kobayashi D., et al.
  2. Novel natriuretic peptides: new compounds and new approaches. Curr Heart Fail Rep. (2011) 8 (1): 22-7. Review. Vogel M.W and Chen H.H.
  3. Biomarkers and heart disease. Eur Rev Med Pharmacol Sci. (2014) 18 (19): 2927-35. Review. Sun R.R., et al.
  4. Roles of atrial natriuretic peptide and its therapeutic use. J Cardiol. (2010) 56 (3): 262-70. Review. Saito Y.
  5. Natriuretic peptides in the pathophysiology of congestive heart failure. Curr Cardiol Rep. (2000) 2 (3): 198-205. Review. Chen H.H. and Burnett J.C.


  • Full Name: Atrial Natriuretic Peptide (ANP) ELISA Kit
  • Reactivity: Human
  • Sample Type: Cell Lysates, Plasma, Cell Culture Supernatant, Serum, Other Biological Fluids
  • Sensitivity: 2.52 ug/ml



Your secretory IgA ELISA kit gave good results and I was also really impressed with how quickly we received it.

L. Johnston
PhD Student / University of Glasgow

It is refreshing to know that you have a technical team that is very knowledgeable. I have already recommended your company to other researchers in our department.

Dr. P. Anderson
Lecturer / University College London (UCL)

I am a first time user and found that your instruction manual was very easy to follow. The insulin ELISA kit performed well and I was happy with the results that were generated.

J. Thomas
Senior Technician / Addenbrooke’s Hospital

I carried out a pilot study comparing the performance of many ELISA kits from different suppliers and found your kits to be one of the better performers. We observed good linearity and tight replicates.

Dr. C. Davies
Lead Scientists / AstraZeneca

You are my first point of contact when I am looking to purchase ELISA kits. You have such an easy and simple system, yet it is very effective.

A. Shaw
Purchasing / University of Oxford